




Supplementary Figures and Tables




**Supplementary Figure 1: Recombination strategy and verification of gene amplification products via PCR.** (A) depicts the recombination strategy for the generation of CD18<sup>fl/fl</sup> mouse. The targeting vector encoded CD18 exon 3 was flanked by loxP sites. After Cre mediated excision, exon 3 of CD18 has been excised from the genome, resulting in a complete CD18 deletion in the specific cell type (here: Ly6G-specific CD18 deletion). The primer pairs used to verify successful Cre-mediated excision of exon 3 are shown in the upper panel (B2\_s and B3\_as). (B) depicts the results from a representative B2/3-PCR (PCR-1). Using the primer pair B2/3 a single 487bp product was amplified in case of CD18<sup>fl/fl</sup> homozygote and a single 233bp product in case of the CD18<sup>wt/wt</sup> mice. (C) shows representative PCR-results for a Ly6G/Cre-PCR (PCR-2). Using the primer pairs previously described by Hasenberg and coworkers and a primer pair detecting  $\beta$ -actin, a single 373bp product was amplified in case of a successful knock-in (Ly6G<sup>Cre+</sup>) and a single 585bp product in case of Cre negative wild-type mice (C57Bl/6). Mice with a floxed CD18 gene as determined in PCR-1 and a Ly6G<sup>Cre+</sup> genotype in PCR-2 were therefore being classified as CD18<sup>Ly6G</sup> cKO mice. Whereas mice without the respective knock-in band in PCR-2 were classified as CD18<sup>fl/fl</sup>.




**Supplementary Figure 2: Representative example of the gating strategy applied in the *in-vivo* experiments.** Gating strategy comprises exclusion of erythrocytes (1), doublets (2) and non-viable cells (3). Subsequently we have identified PMN as CD45+ (4), Ly6G+ and CD11b+ cells (5). Data reveal a significant downregulation of CD11b (6) and CD18 (7) on PMN derived from CD18<sup>Ly6G</sup> cKO mice (red) as compared to CD18<sup>fl/fl</sup> mice (blue).




**Supplementary Figure 3: Downregulation of CD18 is restricted to PMN.** Gating for CD3<sup>+</sup> lymphocytes (left column), Ly6C<sup>high</sup> Ly6G<sup>low</sup> monocytes (center column) and F4/80<sup>+</sup> macrophages (right column) revealed that these leukocyte subpopulations have not been affected by CD18-downregulation (histograms, blue: CD18<sup>fl/fl</sup> mice; red: CD18<sup>Ly6G cKO</sup> mice).




**Supplementary Figure 4:**  $\beta$ 2-integrin subunit surface marker expression on PMN from BALF (A), blood (B) or spleens (C) of IPA-infected CD18<sup>fl/fl</sup> and CD18<sup>Ly6G</sup> cKO mice. We could observe a marked downregulation (30-50%) of all subunits on PMN derived from these compartments in CD18<sup>Ly6G</sup> cKO mice. Data represent the mean  $\pm$  SEM of 6-10 samples analyzed /group during *in-vivo* experiments. Statistically significant differences between groups are indicated (\*\* $p < 0.005$ , \*\*\* $p < 0.001$ ).




**Supplementary Figure 5:** Cytokine measurements from serum of IPA-infected CD18<sup>fl/fl</sup> and CD18<sup>Ly6G</sup> cKO mice. Despite a stronger expression of CCL5 in serum of CD18<sup>fl/fl</sup> mice, results did not reveal significant differences between the different genotypes. Data denote the mean  $\pm$  SEM of 6-10 samples analyzed per group. Statistically significant differences between groups are indicated (\* $p < 0.05$ ).




**Supplementary Figure 6: Share of CD11c<sup>+</sup> PMN among all PMN found in spleens or BALF of CD18<sup>fl/fl</sup> and CD18<sup>Ly6G</sup> cKO mice, respectively.** In accordance with previous reports, we found a small share of PMN with a strong expression of CD11c. CD11c expression among splenic PMN derived from CD18<sup>fl/fl</sup> mice was higher as compared to CD18<sup>Ly6G</sup> cKO mice. No statistically significant differences in CD11c expression on BALF-derived PMN have been observed. Data show the mean  $\pm$  SEM of 6-10 samples analyzed per group. Statistically significant differences between groups are indicated (\*p<0.05).



**Supplementary Figure 7. Relative and absolute numbers of leukocyte subpopulations analyzed in peripheral blood.** No significant differences between the relevant cell populations have been observed. However, as for absolute cell counts, we found a moderate leukocytosis in CD18<sup>Ly6G</sup> cKO mice. Monocytes were classified as Ly6C<sup>high</sup> and Ly6C<sup>-</sup>, whereas PMN were defined as Ly6C<sup>high</sup> and Ly6C<sup>-</sup>. Lymphocytes denote all CD3<sup>+</sup> T cells. Data represent the mean  $\pm$  SEM of 6-10 samples analyzed /group during *in-vivo* experiments.



**Supplementary Figure 8: Gating strategy applied in the experiments analyzing the uptake of GFP-fluorescent *A. fumigatus conidia* (AFC) by PMN.** Here, we could observe a diminished uptake of GFP-fluorescent conidia by PMN isolated from CD18<sup>Ly6G</sup> cKO mice as compared to PMN isolated from CD18<sup>fl/fl</sup> mice (red vs. blue histograms in 8).



**Supplementary Figure 9: Results from in-vitro cytokine analysis of PMN isolated from CD18<sup>fl/fl</sup> and CD18<sup>Ly6G</sup> cKO mice after 3h and 24h of differential treatment.** We have purified PMN from CD18<sup>fl/fl</sup> (n=3) mice and CD18<sup>Ly6G</sup> cKO (n=3) mice and incubated them for 24h at the indicated conditions. After 3h and 24h supernatants have been taken and were analyzed using a CBA. We could detect no significant genotype-dependent differences in cytokine levels of IL-1 $\beta$ , IL-6 or IL-10 in supernatants. Bar charts denote the mean + SEM of cytokine measurements from n=3 experiments.